Net income of Edwards Lifesciences under GAAP for the 3 months of 2022 was $373.6 million, up 10.5% from $338.2 million in the previous year. Revenue increased 10.2% to $1.341 billion from $1.217 billion a year earlier.

Net income of Edwards Lifesciences under GAAP for 2021 was $1.503 billion, up 82.6% from $0.823 billion in the previous year. Revenue increased 19.3% to $5.233 billion from $4.386 billion a year earlier.

Edwards Lifesciences has received FDA approval for the Edwards SAPIEN 3 transcatheter valve system with the Alterra adaptive prestent. The Edwards SAPIEN 3 System is intended to treat adult patients with severe pulmonary regurgitation who have a native or surgically repaired right ventricular outflow tract and are indicated for pulmonary valve replacement.

Net income of Edwards Lifesciences under GAAP for 9M 2021 was $1.168 billion, up 2.3 times from $0.514 billion in the previous year. Revenue increased 22.2% to $3.903 billion from $3.195 billion a year earlier.